{"schema_version":"secwatch.filing_event.v1","accession":"0001232524-23-000025","form_type":"8-K","ticker":"JAZZ","cik":"0001232524","company_name":"Jazz Pharmaceuticals plc","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.198686+00:00","generated_at":"2026-06-15T05:56:12.067150+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Jazz Q1 EPS $1.04, adj. $3.95; rev $893M (+10%); Xywav +49%, guidance affirmed","bullets":["GAAP net income $69.4M ($1.04 EPS) vs $1.6M ($0.03) in 1Q22; non-GAAP adj. net income $285.3M ($3.95 EPS) vs $261.9M ($3.73).","Total revenue $892.8M (+10% YoY); neuroscience $654.0M (+7%), oncology $228.9M (+16%).","Xywav net sales $277.8M (+49%), Epidiolex $188.9M (+20%), Rylaze $85.9M (+58%).","FY 2023 guidance affirmed: rev $3.675-3.875B; GAAP EPS $5.90-$7.90; non-GAAP adj. EPS $16.90-$17.85.","Pipeline: zanidatamab ASCO June 2, JZP150 PTSD Phase 2 top-line late 2023, suvecaltamide ET Phase 2b 1H24."],"urls":{"canonical":"https://secwatch.observer/filing/0001232524-23-000025","json":"https://secwatch.observer/filing/0001232524-23-000025.json","markdown":"https://secwatch.observer/filing/0001232524-23-000025.md","text":"https://secwatch.observer/filing/0001232524-23-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1232524/000123252423000025/0001232524-23-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1232524/000123252423000025/jazz-20230510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T05:56:12.067150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}